BIOSION ACHIEVEMENTS

Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.

Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents

  • 4
    Assets in clinical development
  • 3
    Proprietary technology platforms
  • 10+
    Innovative therapies in preclinical or clinical development
  • 8
    Partnered programs
  • A Diversified Portfolio with Global Vision
  • Patient-centric focus is integral to Biosion’s R&D strategy
  • Portfolio of differentiated biologics to compete on the global stage
RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS
  • Molecule: BSI-045B
    Modality / Target:
    TSLP
    Severe Asthma
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-501
    Modality / Target:
    FIC Bispecific
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-038
    Modality / Target:
    CD40
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-060T
    Modality / Target:
    Siglec-15
    Solid Tumors
    Partner: PYXIS - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-585
    Modality / Target:
    PD1/ILT4
    Solid Tumors
    Partner: Celldex - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-04702
    Modality / Target:
    TROP2 ADC
    Solid Tumors
    Partner: OBI - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-082
    Modality / Target:
    SIRPα
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-001
    Modality / Target:
    HER2
    Solid Tumors
    Partner: ANKEBIO - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-510
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-075
    Modality / Target:
    PVRIG
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
BIOSION ACHIEVEMENTS

Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.

Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents

  • 4
    Assets in clinical development
  • 3
    Proprietary technology platforms
  • 10+
    Innovative therapies in preclinical or clinical development
  • 8
    Partnered programs
  • A Diversified Portfolio with Global Vision
  • Patient-centric focus is integral to Biosion’s R&D strategy
  • Portfolio of differentiated biologics to compete on the global stage
RICH PIPELINE OF BREAKTHROUGH THERAPEUTICS
  • All categories
  • Allergy /immunology
  • Oncology
  • BSI-045B
    Modality / Target:
    TSLP
    Partner
    MORE
    Severe Asthma
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-501
    Modality / Target:
    FIC Bispecific
    Partner
    MORE
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-038
    Modality / Target:
    CD40
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
  • BSI-060T
    Modality / Target:
    Siglec-15
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    PYXIS - Ex China
  • BSI-585
    Modality / Target:
    PD1/ILT4
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Celldex - Ex China
  • BSI-04702
    Modality / Target:
    TROP2 ADC
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    OBI - Ex China
  • BSI-082
    Modality / Target:
    SIRPα
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-001
    Modality / Target:
    HER2
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    ANKEBIO - China
  • BSI-510
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-075
    Modality / Target:
    PVRIG
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
    Biosion’s Mission
    To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
    Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
    BD@Biosion.com
    1-302-998-5126
    Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号